Palliative Care and Hospice Education and Training Act

Issues relating to health disparities, health care reform, quality of life and palliative care, federal health care programs, genetic information, cancer, nutrition, and wellness, including the following legislation: S. 494 and H.R. 912, Colorectal Cancer Prevention, Early Detection & Treatment Act; H.R. 1213, Repeal mandatory funding provided to states in PPACA to establish American Health Benefit Exchanges; H.R. 1217, Repeal Prevention and Public Health Fund; H.R. 1740 and H.R. 5560, the Quality Cancer Care for Life Act of 2010; H.R.2941 and S.3493; H.R.3974, Viral Hepatitis and Liver Cancer Control and Prevention Act of 2009; H.R.4662, the Lymphedema Diagnosis and Treatment Cost Savings Act of 2010; the implementation of P.L. 111-148, the Patient Proection and Affordable Care Act of 2010; S.1064, the Sun Act; S.965, the Family Act; H.R.2954, Health Equity and Accountability Act of 2011; and H.R.2077, the MLR Repeal Act; H.R.2245 and S.296 Preserving Access to Life-Saving Medications Act, issues related to the reauthorization of the prescription drug user fee, S.3187, the FDA Safety and Innovation Act and the House Companion legislation, and issues relating to the ongoing national shortage of cancer drugs, Amendment relating to S.1813, the Moving Ahead for Progress in the 21st Century Act, and H.R.4274, reauthorization of the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act. Issues relating to global health including S.2515, the Clean Cookstoves Support Act of 2012; H.R.6155 & S.3047, the Palliative Care and Hospice Education & Training Act; and H.R.6157, the Patient Centered Quality of Care Act.

Client expense: $810,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Natl Institutes of Health (NIH), SENATE, State, Dept of (DOS), U.S. Agency for International Development (USAID), White House Office

Issues surrounding the enactment or repeal of the Affordable Care Act, including IPAB and ACOs. Medicare reimbursement for providers. FDA Reauthorization. Issues surrounding the tissue bank industry. HR 452: Medicare Decisions Accountability Act (IPAB repeal). S 668: Health Care Bureaucrats Elimination Act (IPAB repeal) HR 1845, S 960: Medicare IVIG Access Act. HR 5: Protecting Access to Healthcare Act (Medical Liability Reform) HR 1955, S. 1045: Children's Access to Reconstructive Evaluation and Surgery Act. HR 6155: Palliative Care and Hospice Education and Training Act.

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues relating to health disparities, health care reform, quality of life and palliative care, federal health care programs, genetic information, cancer, nutrition, and wellness, including the following legislation: S. 494 and H.R. 912, Colorectal Cancer Prevention, Early Detection & Treatment Act; H.R. 1213, Repeal mandatory funding provided to states in PPACA to establish American Health Benefit Exchanges; H.R. 1217, Repeal Prevention and Public Health Fund; H.R. 1740 and H.R. 5560, the Quality Cancer Care for Life Act of 2010; H.R.2941 and S.3493; H.R.3974, Viral Hepatitis and Liver Cancer Control and Prevention Act of 2009; H.R.4662, the Lymphedema Diagnosis and Treatment Cost Savings Act of 2010; the implementation of P.L. 111-148, the Patient Proection and Affordable Care Act of 2010; S.1064, the Sun Act; S.965, the Family Act; H.R.2954, Health Equity and Accountability Act of 2011; and H.R.2077, the MLR Repeal Act; H.R.2245 and S.296 Preserving Access to Life-Saving Medications Act, issues related to the reauthorization of the prescription drug user fee, S.3187, the FDA Safety and Innovation Act and the House Companion legislation, and issues relating to the ongoing national shortage of cancer drugs, Amendment relating to S.1813, the Moving Ahead for Progress in the 21st Century Act, and H.R.4274, reauthorization of the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act. Issues relating to global health including S.2515, the Clean Cookstoves Support Act of 2012; H.R.6155 & S.3047, the Palliative Care and Hospice Education & Training Act; and H.R.6157, the Patient Centered Quality of Care Act.

Client expense: $620,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Natl Institutes of Health (NIH), SENATE, State, Dept of (DOS), U.S. Agency for International Development (USAID), White House Office